Therapeutic effects of micro-RNAs in preclinical studies of acute kidney injury: a systematic review and meta-analysis
| Autor: | Adrian Bailey, Kevin D. Burns, Jose L. Viñas, Rosendo A. Rodriguez, Sarah Zankar, David S. Allan, Mayra Trentin-Sonoda |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Male Science 030232 urology & nephrology Drug Evaluation Preclinical Renal function Apoptosis Pathogenesis Bioinformatics Kidney Article 03 medical and health sciences chemistry.chemical_compound Mice 0302 clinical medicine medicine PTEN Animals Adverse effect Creatinine Multidisciplinary Kidney diseases biology business.industry Acute kidney injury Antagomirs Acute Kidney Injury medicine.disease 3. Good health Rats Experimental models of disease MicroRNAs 030104 developmental biology medicine.anatomical_structure chemistry Nephrology Preclinical research Meta-analysis biology.protein Medicine Female business Kidney disease |
| Zdroj: | Scientific Reports, Vol 11, Iss 1, Pp 1-12 (2021) Scientific Reports |
| ISSN: | 2045-2322 |
| Popis: | AKI has a high mortality rate, may lead to chronic kidney disease, and effective therapies are lacking. Micro-RNAs (miRNAs) regulate biologic processes by potently inhibiting protein expression, and pre-clinical studies have explored their roles in AKI. We conducted a systematic review and meta-analysis of miRNAs as therapeutics in pre-clinical AKI. Study screening, data extraction, and quality assessments were performed by 2 independent reviewers. Seventy studies involving 42 miRNA species were included in the analysis. All studies demonstrated significant effects of the miRNA intervention on kidney function and/or histology, with most implicating apoptosis and phosphatase and tensin homolog (PTEN) signaling. Fourteen studies (20.0%) examined the effect of miRNA-21 in AKI, and meta-analysis demonstrated significant increases in serum creatinine and kidney injury scores with miR-21 antagonism and pre-conditioning. No studies reported on adverse effects of miRNA therapy. Limitations also included lack of model diversity (100% rodents, 61.4% ischemia–reperfusion injury), and predominance of male sex (78.6%). Most studies had an unclear risk of bias, and the majority of miRNA-21 studies were conducted by a single team of investigators. In summary, several miRNAs target kidney function and apoptosis in pre-clinical AKI models, with data suggesting that miRNA-21 may mediate protection and kidney repair.Systematic review registration ID: CRD42019128854. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |